DBV Technologies: Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance
(Thomson Reuters ONE) -
Press Release
Montrouge, France, March 6, 2016
Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016
AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
that results from the OLFUS-VIPES trial were presented at the 2016 AAAAI meeting
in Los Angeles, California. During the late-breaking oral session
Clinical/Translational Sciences, Dr. Hugh Sampson, Principal Investigator of the
OLFUS-VIPES study, presented data that continued to support the favorable
safety, efficacy and tolerability of Viaskin Peanut in peanut allergic patients.
OLFUS-VIPES is the ongoing, open-label, two year follow-up study of VIPES, the
company's Phase IIb clinical trial of Viaskin® Peanut. DBV reported positive
topline results for OLFUS-VIPES in October 2015, and presented additional data
at the 2016 AAAAI meeting.
Clinical trial results continued to support the safety and tolerability profile
of Viaskin® Peanut. There were no treatment-related serious adverse events
observed during the trial nor use of epinephrine associated with treatment. No
trial participant drop-outs due to drug-related adverse events were reported.
The majority of adverse events were mild and moderate, consisting primarily of
application site symptoms, with frequency decreasing over time. Additionally,
high treatment adherence was also observed - a compliance rate of more than 96%
across all cohorts was reported.
Dr. Sampson also showed during his presentation that 80% of children ages six to
11 years responded to Viaskin Peanut 250 µg in the trial. After 24 months, the
average cumulative reactive dose (CRD) in this treatment group was 1,883 mg
(1,440 mg median) peanut protein compared to 84 mg (44 mg median) at baseline. A
doubling in response rates at 1,000 mg or more during the oral food challenge
was observed during the second year of treatment in children dosed with Viaskin
Peanut 250 µg, which increased to 60%. For reference, one peanut contains
approximately 250 mg of peanut protein.
Dr. Hugh Sampson, Director of the Jaffe Food Allergy Institute at the Kravis
Children's Hospital at Mount Sinai; Principal Investigator of the OLFUS-VIPES
study; and Chief Scientific Officer, DBV Technologies, said: "Data from OLFUS-
VIPES support an increase in treatment response over time. Patients were highly
motivated and we saw excellent treatment compliance and no treatment-related
dropouts. I believe this is a unique feature of Viaskin Peanut, which continues
to show a strong safety profile," said Dr. Sampson. "We also continue to observe
a significant increase in the level of peanut protein consumed by patients that
have been treated for two years"
Chosen by AAAAI as a late-breaking presentation, in "Enhanced Efficacy and
Confirmed Safety of a Two-Year Epicutaneous Immunotherapy (EPIT®) Treatment of
Peanut Allergy with Viaskin® Peanut: The Continuation of the VIPES Phase IIb
Randomized Controlled Trial" Dr. Sampson concluded that Viaskin® Peanut
continued to demonstrate a favorable safety profile along with an observed
increase in treatment response over time. The open-label extension included 171
subjects from the VIPES Phase IIb clinical trial, who transitioned to the 250 µg
dose of Viaskin® Peanut during OLFUS-VIPES.
Viaskin was also observed to maintain response rates in adolescents and adults
over time. Based on these results, DBV intends to explore additional Viaskin
Peanut dose regimens in populations not included in the ongoing Phase III trial,
which is studying Viaskin Peanut in children four to 11 years of age.
Other DBV Technologies Presentations at AAAAI
Two additional oral presentations at the AAAAI meeting featured new clinical
data with Viaskin® Peanut. Presented by investigators from the Consortium of
Food Allergy Research (CoFAR) funded by the National Institute of Allergy and
Infectious Diseases, part of the National Institutes of Health (NIH), results
from the CoFAR6 study showed that treatment with Viaskin® Peanut was observed to
be safe and well-tolerated, and it led to statistically significant
desensitization compared to placebo. The data showed that cohorts treated with
both Viaskin Peanut 100 µg (p=0.005), and Viaskin Peanut 250 µg (p=0.003) met
the primary endpoint in all populations, with an enhanced treatment response
observed in children four to 11 years of age.
An oral presentation and seven poster sessions highlighting the use of
Epicutaneous Immunotherapy (EPIT) were also featured during the AAAAI meeting.
Clinical data from Viaskin Milk in cow's milk allergic patients was highlighted
in a poster session and several mechanistic models showing EPIT's novel
mechanism of action were also showcased.
On Sunday, March 6, DBV Technologies will host a Symposium, "Epicutaneous
Immunotherapy - A Novel Pathway In Development for The Treatment of Food
Allergies," from 6:30 - 8:30 PM at the Diamond Ballroom Level, Salon 4 at the JW
Marriott Los Angeles L.A. LIVE. The Symposium will be broadcasted live and
archived online at http://www.dbv-technologies.com/en/news-events/scientific-
congresses.
About OLFUS-VIPES Section
OLFUS enrolled 171 subjects who had previously received either placebo or one of
three 12-month dose regimens administered during VIPES. During the first year of
OLFUS, patients were to receive a daily application of Viaskin® Peanut 50 µg or
Viaskin® Peanut 100 µg or Viaskin® Peanut 250 µg for 12 months. According to a
study protocol change implemented in March 2014, all patients were switched to
receive Viaskin® Peanut 250 micrograms during OLFUS. Baseline response levels in
OLFUS were based on the results of the last double-blind, placebo controlled
food challenge (DBPCFC) in VIPES, and adjusted by the number of patients
enrolling in OLFUS. As in VIPES, a responder in the OLFUS trial was defined as a
subject who could reach a peanut protein eliciting dose equal to or greater than
1,000 mg peanut protein during the 12-month DBPCFC or a subject with a greater
than or equal to 10-fold increase of the eliciting dose compared to the initial
eliciting dose after 12 months of treatment. Patients enrolled in OLFUS who
received placebo in VIPES were analyzed separately from subjects who initially
received Viaskin® Peanut.
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the
treatment of allergies - a major public health issue that has been increasing in
prevalence. DBV Technologies, incorporated in France in 2002, has developed a
proprietary, patented technology for administering an allergen to intact skin
while avoiding transfer to the blood, and thus lowering the risk of a systemic,
allergic reaction in the event of accidental exposure. DBV Technologies is
focusing on food allergies, including milk and peanut, for which there are
currently no effective treatments. DBV Technologies has designed two products
candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program
for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy
designation from the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American
Depositary Shares (each representing one-half of one ordinary share) (Ticker:
DBVT). For more information on DBV Technologies, please visit our website:
www.dbv-technologies.com
Forward Looking Statements
This press release contains forward-looking statements, including statements
about the potential safety and efficacy of Epicutaneous Immunotherapy (EPIT®)
via Viaskin® Peanut and DBV's anticipated clinical development of Viaskin
Peanut. These forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. The Company's product candidates
have not been approved for sale in any jurisdiction. Among the factors that
could cause actual results to differ materially from those described or
projected herein are uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and approvals, the
risk that historical preclinical results may not be predictive of future
clinical trial results, and the risk that historical clinical trial results may
not be predictive of future trial results. A further list and description of
these risks, uncertainties and other risks can be found in the Company's
regulatory filings with the French Autorité des Marchés Financiers, the
Company's Securities and Exchange Commission filings and reports, including in
the Company's Annual Report on Form 20-F for the year ended December 31, 2014
and future filings and reports by the Company. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. DBV Technologies undertakes
no obligation to update or revise the information contained in this Press
Release, whether as a result of new information, future events or circumstances
or otherwise.
DBV Technologies Contacts
Nathalie Donne Susanna Mesa
Director, Corporate Communication & VP Finance, US Investor Relations &
Business Development Strategy
Tel. : +33(0)1 55 42 78 72 Tel. : +1 212-271-0861
nathalie.donne(at)dbv-technologies.com susanna.mesa(at)dbv-technologies.com
DBV Technologies Media Contacts US & Europe
Marion Janic Caroline Carmagnol
Rooney & Associates Alize RP - Relation Presse
Tel. : +1-212-223-4017 Tel. : +33(0)6 64 18 99 59
mjanic(at)rooneyco.com caroline(at)alizerp.com
Erinn White
Centron PR
Tel. : +1-646-722-8822
ewhite(at)centronpr.com
PDF Version:
http://hugin.info/156437/R/1992161/733154.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#1992161]
Unternehmensinformation / Kurzprofil:
Datum: 06.03.2016 - 23:01 Uhr
Sprache: Deutsch
News-ID 455463
Anzahl Zeichen: 12000
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 259 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies: Additional Phase IIb Trial Results with Viaskin Peanut Presented at the 2016 AAAAI Meeting Continue to Support Treatment Safety, Efficacy and Compliance"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
